Recent studies of large MDS cohorts have defined WT1 mutations as an independent poor prognostic indicator [16], and have shown correlations of WT1 mutations with lower hemoglobin levels and a higher percentage of bone marrow blasts [17]. This evidence concerns the gene WT1 and myelodysplastic syndrome.